Depression and bipolar disorder: Relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 60, Issue 4, 1999, Pages 217-234

  Horrobin, D F ^a   Bennett, C N ^a  

^a Laxdale Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; ICOSAPENTAENOIC ACID; LITHIUM; OLANZAPINE; PHOSPHOLIPID; PROSTAGLANDIN; RISPERIDONE;

AGING; CANCER; CARDIOVASCULAR DISEASE; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; FATTY ACID METABOLISM; GENETIC PREDISPOSITION; HUMAN; IMMUNOPATHOLOGY; MANIC DEPRESSIVE PSYCHOSIS; MULTIPLE SCLEROSIS; OSTEOPOROSIS; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 0032981266     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.1999.0037     Document Type: Article

References (252)

1. Hibbeln J. R. Fish consumption and major depression. Lancet. 351:1998;1213.
2. Keck P E., McElroy S. L. Jr, Strakowski S. M. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry. 155:1998;646-652.
3. Hlastala S. A., Frank E., Mallinger A. G., Thase M. E., Ritenou A. M., Kupfer D. J. Bipolar depression: an underestimated treatment challenge. Depression Anxiety. 5:1997;78-83.
4. Sporn J., Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol. 17:1997;185-189.
5. Calabrese J. R., Rapport D. J., Shelton M. D., Kimmel S. E. Clinical studies on the use of lamotrigine in bipolar disorder. Neuropsychobiology. 38:1998;185-191.
6. Peet M., Edwards R. W. Lipids, depression and physical diseases. Curr Opinon Psychiatry. 10:1997;477-480.
7. Franco Bronson K. The management of treatment-resistant depression in the medically ill. Psychiatr Clin North Am. 19:1996;329-350.
8. Black S. A., Goodwin J. S., Markides K. S. The association between chronic diseases and depressive symptomatology in older Mexican Americans. J Gerontol. 53:1998;M188-M194.
9. Engedal K. Mortality in the elderly - A 3-year follow-up of an elderly community sample. Int J Geriatr Psychiatry. 11:1996;467-471.
10. Miller M. D., Paradis C. F., Houck P. R. Chronic medical illness in patients with recurrent major depression. Am J Geriatr Psychiatry. 4:199G;281-290.
11. Ahto M., Isoaho R., Puolijoki H., Laippala P., Romo M., Kivela S. L. Coronary heart disease and depression in the elderly - a population-based study. Fam Pract. 14:1997;436-445.
12. Hippisley-Cox J., Fielding K., Pringle M. Depression as a risk factor for ischaemic heart disease in men: population based case-control study. Br Med J. 316:1998;1714-1719.
13. Carpiniello B., Mercuro G., Balloi C. Chronic heart disease and psychiatric disorders: Results of a prevalence study. Eur J Intern Med. 7:1996;87-92.
14. Carney R. M., Rich M. W., Tevelde A., Saini J., Clark K., Jaffe A. S. Major depressive disorder in coronary artery disease. Am J Cardiol. 60:1987;1273-1275.
15. Carney R. M., Freedland K. E., Rich M. W., Smith L. J., Jaffe A. S. Ventricular tachycardia and psychiatric depression in patients with coronary artery disease. Am J Med. 95:1993;23-27.
16. Carney R. M., Freedland K. E., Rich M. W., Jaffe A. S. Depression as a risk factor for cardiac events in established coronary heart disease: A review of possible mechanisms. Ann Behav Med. 17:1995;142-149.
17. Carney R. M., Freedland K. E., Veith R. C. Major depression, heart rate, and plasma norepinephrine in patients with coronary heart disease. Biol Psychiatry. 45:1999;458-463.
18. Steffens D. C., OÖConnor C. M., Jiang W. J. The effect of major depression on functional status in patients with coronary artery disease. J Am Geriatr Soc. 47:1999;319-322.
19. Frasure Smith N., Lesperance F., Juneau M., Talajic M., Bourassa M. G. Gender, depression, and one-year prognosis after myocardial infarction. Psychosom Med. 61:1999;26-37.
20. Lochen M. L., Rasmussen K. Palpitations and lifestyle: Impact of depression and self-rated health. The Nordland Health Study. Scand J Soc Med. 24:1996;140-144.
21. Everson S. A., Roberts R. E., Goldberg D. E., Kaplan G. A. Depressive symptoms and increased risk of stroke mortality over a 29-year period. Arch Intern Med. 158:1998;1133-1138.
22. Barefoot J. C., Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation. 93:1996;1976-1980.
23. Pratt L. A., Ford D. E., Eaton W. W. Depression, psychotropic medication, and risk of myocardial infarction: prospective date from the Baltimore ECA follow-up. Circulation. 94:1996;3123-3129.
24. Schwartz S. W., Cornoni Huntley J., Cole S. R., Hays J. C., Blazer D. G., Schocken D. D. Are sleep complaints an independent risk factor for myocardial infarction. Ann Epidemiol. 8:1998;384-392.
25. Aromaa A., Raitasalo R., Reunanen A. Depression and cardiovascular diseases. Acta Psychiatr Scand Suppl. 89:1994;77-82.
26. Shapiro P. A. Psychiatric aspects of cardiovascular disease. Psychiatr Clin North Am. 19:1996;613-629.
27. Siever L. J., Uhde T. W., Insel T. R. Biological alterations in the primary affective disorders and other tricyclic-responsive disorders. Prog Neuro-Pychopharmacol Biol Psychiat. 9:1985;15-24.
28. Musselman D. L., Tomer A., Manatunga A. K. Exaggerated platelet reactivity in major depression. Am J Psychiatry. 153:1996;1313-1317.
29. Agewall S., Wikstrand J., Dahlof C., Fagerberg B. Negative feelings (discontent) predict progress of intima-media thickness of the common carotid artery in treated hypertensive men at high cardiovascular risk. Am J Hypertens. 9:1996;545-550.
30. Carney C. Diabetes mellitus and major depressive disorder: An overview of prevalence, complications, and treatment. Depression Anxiety. 7:1998;149-157.
31. Eiber R., Berlin T., Grimaldi A., Bisserbe J. C. Insulin dependent diabetes mellitus and psychiatric disorders. Encephale. 23:1997;351-357.
32. Gavard J. A., Lustman P. J., Clouse R. E. Prevalence of depression in adults with diabetes. An epidemiological evaluation. Diabetes Care. 16:1993;1167-1178.
33. Goodnick P. J., Henry J. H., Buki V. M. V. Treatment of depression in patients with diabetes mellitus. J Clin Psychiatry. 56:1995;128-136.
34. Jacobson A. M. Depression and diabetes. Diabetes Care. 16:1993;1621-1623.
35. Kovacs M., Obrosky D. S., Goldston D., Drash A. Major depressive disorder in youths with IDDM. Diabetes Care. 20:1997;45-51.
36. Winocour P. H., Main C. J., Medlicott G., Anderson D. C. A psychometric evaluation of adult patients with type 1 (insulin-dependent) diabetes mellitus: prevalence of psychological dysfunction and relationship to demographic variables, metabolic control and complications. Diabetes Res. 14:1990;171-176.
37. Amato L., Paolisso G., Cacciatore F. Non-insulin-dependent diabetes mellitus is associated with a greater prevalence of depression in the elderly. Diabetes Metabol. 22:1996;314-318.
38. Lustman P. J., Griffith L. S., Gavard J. A., Clouse R. E. Depression in adults with diabetes. Diabetes Care. 15:1992;1631-1639.
39. Stolk R. P., Breteler M. M. B., Ott A. Insulin and cognitive function in an elderly population: The Rotterdam study. Diabetes Care. 20:1997;792-795.
40. Jacobson A. M., De Groot M., Samson J. A. The effects of psychiatric disorders and symptoms on quality of life in patients with Type I and Type II diabetes mellitus. Qual Life Res. 6:1997;11-20.
41. Goodnick P. J., Kumar A., Henry J., Buki V. M. V., Goldberg R. Sertraline in coexisting major depression and diabetes mellitus. Psychopharmacol Bull. 33:1997;261-264.
42. Lustman P. J., Griffith L. S., Clouse R. E. Effects of nortriptyline on depression and glycemic control in diabetes: Results of a double-blind, placebo-controlled trial. Psychosom Med. 59:1997;241-250.
43. Sumiyoshi T., Ichikawa J., Meltzer H. Y. The effect of streptozotocin-induced diabetes on dopamine-2, serotonin(1A) and serotonin(2A) receptors in the rat brain. Neuropsychopharmacology. 16:1997;183-190.
44. Miyaoka H., Suzuki Y., Taniyama M. Mental disorders in diabetic patients with mitochondrial transfer RNA (Leu (UUR)) mutation at position 3243. Biol Psychiatry. 42:1997;524-526.
45. Smith R. S. The macrophage theory of depression. Med Hypotheses. 35:1991;298-306.
46. Leonard B. E. Stress and the immune system: immunological aspects of depressive illness. International Review of Psychiatry. 2:1990;209-218.
47. Maes M., Scharpe S., Bosmans E. Disturbances in acute phase plasma proteins during melancholia: Additional evidence for the presence of an inflammatory process during that illness. Prog Psychopharmacol Biol Psychiatry. 16:1992;501-515.
48. Maes M. Evidence for an immune response in major depression: A review and hypothesis. Prog Neuro Psychopharmacol Biol Psychiatry. 19:1995;11-38.
49. Ader R., Cohen N., Felten D. Psychoneuroimmunology: Interactions between the nervous system and the immune system. Lancet. 345:1995;99-103.
50. Maes M., Smith R., Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology. 20:1995d;111-116.
51. Price L. H., Rasmussen S. A. Stress and depression: is neuroimmunology the missing link. Harv Rev Psychiatry. 5:1997;108-112.
52. Muller N. The role of the cytokine network in the CNS and psychic disorders. Nervenarzt. 68:1997;11-20.
53. Anderson J. L. The immune system and major depression. Adv Neuroimmunol. 6:1996;119-129.
54. Leonard B. E., Song C. Stress and the immune system in the etiology of anxiety and depression. Pharmacol Biochem Behav. 54:1996;299-303.
55. Fricchione G. L., Bilfinger T. V., Stefano G. B. The macrophage and neuropsychiatric disorders. Neuropsychiatry Neuropsychol Behav Neurol. 9:1996;16-29.
56. Connor T. J., Leonard B. E. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 62:1998;583-606.
57. Maes M. A review on the acute phase response in major depression. Rev Neurosci. 4:1993;407-416.
58. Holden R. J., Pakula I. S., Mooncy P. A. A neuroimmunological model of schizophrenia and major depression: A review. Hum Psychopharmacol. 12:1997;177-201.
59. Arborelius L., Owens M. J., Plotsky P. M., Nemeroff C. B. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol. 160:1999;1-12.
60. Frommberger U. H., Bauer J., Haselbauer P., Fraulin A., Riemann D., Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci. 247:1997;228-233.
61. Brambilla F., Maggioni M. Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatr Scand. 97:1998;309-313.
62. Song C., Lin A. H., Bonaccorso S. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affect Disord. 49:1998;211-219.
63. Maes M., Meltzer H. Y., Bosmans E. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord. 34:1995b;301-309.
64. Seidel A., Arolt V., Hunstiger M., Rink L., Behnisch A., Kirchner H. Cytokine production and serum proteins in depression. Scand J Immunol. 41:1995;534-538.
65. Maes M., Bosmans E., Meltzer H. Y. Immunoendocrine aspects of major depression - Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol. Eur Arch Psychiatry Clin Neurosci. 245:1995;172-178.
66. Maes M., Sharpe S., Meltzer H. Y. Increased neopterin and Interferon-gamma secretion and lower availability of L-tryptophan in major depression: Further evidence for an immune response. Psychiatry Res. 54:1994;143-160.
67. Maes M., Meltzer H. Y., Buckley P., Bosmans E. Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci. 244:1995c;325-329.
68. Inglot A. D., Leszek J., Piasecki E., Sypula A. Interferon responses in schizophrenia and major depressive disorders. Biol Psychiatry. 35:1994;464-473.
69. Maes M., Vandoolaeghe E., Van Hunsel F. Immune disturbances in treatment-resistant depression: modulation by antidepressive treatments. Hum Psychopharmacol. 12:1997;153-162.
70. Sluzewska A., Rybakowski J., Bosmans E. Indicators of immune activation in major depression. Psychiatry Res. 64:1996;161-167.
71. Maes M., Vandoolaeghe E., Ranjan R., Bosmans E., Bergmans R., Desnyder R. Increased serum interleukin-1-receptor-antagonist concentrations in major depression. J Affect Disord. 36:1995e;29-36.
72. Maes M., Stevens W. J., Declerck L. S. Significantly increased expression of T-cell activation markers (interleukin-2 and HLA-DR) in depression: further evidence for an inflammatory process during that illness. Prog Neuropsychopharmacol Biol Psychiatry. 17:1993;241-255.
73. Nasr S., Altman E. G., Meltzer H. Y. Concordance of atopic and affective disorders. J Affect Disord. 3:1981;291-296.
74. Marshall P. S. Allergy and depression: a neurochemical threshold model of the relation between the illnesses. Psychol Bull. 113:1993;23-43.
75. Hashiro M., Okumura M. The relationship between the psychological and immunological state in patients with atopic dermatitis. J Dermatol Sci. 16:1998;231-235.
76. Lemonnier E., Condat B., Paillere Martinot M. L., Chollet R., Allilaire J. F. Single case report: Paranoia reaction during treatment with interferon. Ann Med Psychol. 154:1996;246-249.
77. Licinio J., Kling M. A., Hauser P. Cytokines and brain function: Relevance to interferon-alpha-induced mood and cognitive changes. Semin Oncol. 25:1998;30-38.
78. Hunt C. M., Dominitz J. A., Bute B. P., Waters B., Blasi U., Williams D. M. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci. 42:1997;2482-2486.
79. Neilley L. K., Goodin D. S., Goodkin D. E., Hauser S. L. Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology. 46:1996;552-554.
80. Whitlock F. A., Siskind M. M. Depression as a major symptom of multiple sclerosis. J Neurol Neurosurg Psychiatry. 43:1980;861-865.
81. Ron M. A., Logsdail S. J. Psychiatric morbidity in multiple sclerosis: a clinical and MRI study. Psychol Med. 19:1989;887-895.
82. Schiffer R. B., Caine E. D., Bamford K. A., Levy S. Depressive episode in patients with multiple sclerosis. Am J Psychiatry. 140:1983;1498-1500.
83. Schubert D. S. P., Foliart R. H. Increased depression in multiple sclerosis patients: a meta analysis. Psychosomatics. 34:1993;124-130.
84. Feinstein A. Multiple Sclerosis, depression and suicide. Br Med J. 315:1997;691-692.
85. Horrobin D. F., Lieb J. A biochemical basis for the actions of lithium on behaviour and on immunity: relapsing and remitting disorders of inflammation and immunity such as multiple sclerosis or recurrent herpes as manic-depression of the immune system. Med Hypotheses. 7:1981;891-905.
86. Kellner C. H., Davenport Y., Post R. M., Ross R. J. Rapidly cycling bipolar disorder and multiple sclerosis. Am J Psychiatry. 141:1984;112-113.
87. Minden S. I., Schiffer R. B. Affective disorders in multiple sclerosis. Arch Neurol. 47:1990;98-104.
88. Massie M. J., Gagnon P., Holland J. C. Depression and suicide in patients with cancer. J Pain Symptom Manage. 9:1994;325-340.
89. McDaniel J. S., Musselman D. L., Porter M. R., Reed D. A., Nemeroff C. B. Depression in patients with cancer: diagnosis, biology, and treatment. Arch Gen Psychiatry. 52:1995;89-99.
90. Cousins J. P., Harper G. Neurobiochemical changes from Taxol/Neupogen chemotherapy for metastatic breast carcinoma corresponds with suicidal depression. Cancer Lett. 110:1996;163-167.
91. Iwagaki H., Hizuta A., Uomoto M., Takeuchi Y., Saito S., Tanaka N. Cancer cachexia and depressive states: a neuro-endocrine-immunological disease. Acta Med Okayama. 51:1997;233-236.
92. Purasiri P., Murray A., Richardson S., Heys S. D., Horrobin D. F., Eremin O. Modulation of cytokine production in vivo by dietary essential fatty acids in patients with colorectal cancer. Clin Sci. 87:1994;711-717.
93. Allen-Mersh T. G., Glover C., Fordy C., Henderson D. C., Davies M. Relation between depression and circulating immune products in patients with advanced colorectal cancer. J R Soc Med. 91:1998;408-413.
94. Lebowitz B. D., Pearson J. L., Schneider L. S. Diagnosis and treatment of depression in late life: consensus statement update. J Am Med Assoc. 278:1997;1186-1190.
95. Valvanne J., Juva K., Erkijuntti T., Tilvis R. Major depression in the elderly: a population study in Helsinki. Int J Psychogeriatics. 8:1996;437-443.
96. Burvill P. W., Hall W. D., Stampfer H. G., Emmerson J. P. The prognosis of depression in old age. Br J Psychiatry. 158:1991;64-71.
97. Wassertheil-Smoller S., Applegate W. B., Berge K. Change in depression as a precursor of cardiovascular events. Arch Intern Med. 156:1996;553-561.
98. Healy D. The Antidepressant Era. 1997;University Press, Cambridge: Harvard.
99. el Mallakh R. S., Li R. Is the Na(+)-K(+)-ATPase the link between phosphoinositide metabolism and bipolar disorder. J Neuropsychiatry Clin Neurosci. 5:1993;361-368.
100. Hudson C. J., Young L. T., Li P. P., Warsh J. J. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders. Synapse. 13:1993;278-293.
101. Soares J. C., Mallinger A. G. Intracellular phosphatidylinositol pathway abnormalities in bipolar disorder patients. Psychopharmacol Bull. 33:1997;685-691.
102. Stoll A. L., Severus W. E. Mood stabilizers: shared mechanisms of action at postsynaptic signal-transduction and kindling processes. Harv Rev Psychiatry. 4:1996;77-89.
103. Manji H. K., Lenox R. H. Lithium: a molecular transducer of mood-stabilization in the treatment of bipolar disorder. Neuropsychopharmacology. 19:1998;161-166.
104. Duman R. S., Heninger G. R., Nestler E. J. A molecular and cellular theory of depression. Arch Gen Psychiatry. 54:1997;597-606.
105. Stoll A. L., Locke C. A., Marangell L. B., Severus W. E. Omega-3 fatty acids and bipolar disorder: a review. Prostaglandins Leukot Essent Fatty Acids. 1999.
106. Volz H. P., Rzanny R., Riehemann S. P-31 magnetic resonance spectroscopy in the frontal lobe of major depressed patients. Eur Arch Psychiatry Clin Neurosci. 248:1998;289-295.
107. Lachman H. M., Papolos D. F. Abnormal signal transduction: a hypothetical model for bipolar affective disorder. Life Sci. 45:1989;1413-1426.
108. Post R. M., Ketter T. A., Denicoff K. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology Berl. 128:1996;115-129.
109. Deicken R. F., Weiner M. W., Fein G. Decreased temporal lobe phosphomonoesters in bipolar disorder. J Affect Disord. 33:1995;195-199.
110. Kato T., Shiori T., Murashita J., Hamakawa H., Inubushi T., Takahashi S. Phosphorus-31 magnetic resonance spectroscopy and ventricular enlargement in bipolar disorder. Psychiatry Res Neuroimaging. 55:1994;41-50.
111. Kato T., Shioiri T., Takahashi S., Inubushi T. Measurement of brain phosphoinositide metabolism in bipolar patients using in vivo 31P-MRS. J Affect Disord. 22:1991;185-190.
112. Chen G., Manji H. K., Hawver D. B., Wright C. B., Potter W. Z. Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem. 63:1994;2361-2364.
113. Berridge M. J., Irvine R. F. Inositol phosphates and cell signalling. Nature. 341:1989;197-205.
114. Jope R. S. A bimodal model of the mechanism of action of lithium. Mol Psychiatry. 4:1999;21-25.
115. Manji H. K., Bersudsky Y., Chen G., Belmaker R. H., Potter W. Z. Modulation of protein kinase C isozymes and substrates by lithium: the role of myo-inositol. Neuropsychopharmacology. 15:1996;370-381.
116. Chang M. C.J., Grange E., Rabin O., Bell J. M., Allen D. D., Rapoport S. I. Lithium decreases turnover of arachidonate in several brain phospholipids. Neurosci Lett. 220:1996;171-174.
117. Chang M. C. J., Jones C. R. Chronic lithium treatment decreases brain phospholipase A(2) activity. Neurochem Res. 23:1998;887-892.
118. Chang M. C. J., Bell J. M., Purdon A. D., Chikhale E. G., Grange E. Dynamics of docosahexaenoic acid metabolism in the central nervous system: lack of effect of chronic lithium treatment. Neurochem Res. 24:1999;399-406.
119. Manku M. S., Horrobin D. F., Karmazyn M., Cunnane S. C. Prolactin and zinc effects on rat vascular reactivity: possible relationship to dihomo-gamma-linolenic acid and to prostaglandin synthesis. Endocrinology. 104:1979;774-779.
120. Karmazyn M., Manku M. S., Horrobin D. F. Changes of vascular reactivity induced by low vasopressin concentrations: interactions with cortisol and lithium and possible involvement of prostaglandins. Endocrinology. 102:1978;1230-1236.
121. Abdulla Y. H., Hamadah K. Effect of ADP on PGE1 formation in blood platelets from patients with depression, mania and schizophrenia. Brit J Psychiat. 127:1975;591-595.
122. Horrobin D. F. Lithium as a regulator of prostaglandin synthesist. Cooper T., Kline W. S., Schou M. Lithium. 1979;854-880 Armsterdam Excerpta Medica.
123. Horrobin D. F., Manku M. S. Possible role of prostaglandin E1 in the affective disorders and in alcoholism. Br Med J. 280:1980;1363-1366.
124. Horrobin D. F. Lithium, fatty acids and seborrhoeic dermatitis: A new mechanism of lithium action and a new treatment for seborrhoeic dermatitis. Lithium. 1:1990;149-155.
125. Sasaki Y., Fujikawa T., NaGao M., Mori K., Yamawaki S. Effect of prostaglandin E1 on vascular depression. July 1998;21st CINP Congress, Glasgow.
126. Vial D., Piomelli D. Dopamine D2 receptors potentiate arachidonate release via activation of cytosolic, arachidonate-specific phospholipase A2. J Neurochem. 64:1995;2765-2772.
127. Garcia M. C., Kim H. -Y. Mobilization of arachidonate and docosahexaenoate by stimulation of the 5-HT2a receptor in rat C6 glioma cells. Brain Res. 768:1997;43-48.
128. Pandey S. C., Davis J. M., Pandey G. N. Phosphoinositide system-linked serotonin receptor subtypes and their pharmacological properties and clinical correlates. J Psychiatry Neurosci. 20:1995;215-225.
129. Strosznajder J., Samochocki M., Duran M. Serotonin, a potent modulator of arachidonic acid turnover, interaction with glutamatergic receptor in brain cortex. Neurochem Int. 25:1994;193-199.
130. Piomelli D., Pilon C., Giros B., Sokoloff P., Martres M. P., Schwartz J. C. Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism. Nature. 353:1991;164-167.
131. Ellis F. R., Sanders T. A. Long chain polyunsaturated fatty acids in endogenous depression. J Neurol Neurosurg Psychiatry. 40:1977;168-169.
132. Fehily A. M. A., Bowey O. A. M., Ellis F. R. Meade B. W. Plasma and erythrocyte membrane long chain polyunsaturated fatty acids in endogenous depression. Neurochem Int. 3:1981;37-42.
133. Adams P. B., Lawson S., Sanigorski A., Sinclair A. J. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids. 31:1996;S157-S161.
134. Maes M., Smith R., Christophe A., Cosyns P., Desnyder. R., Meltzer H. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20:4 omega 6/C20: 5 omega 3 ratio in cholesteryl esters and phosopholipids. J Affective Disord. 38:1996;35-46.
135. Maes, M. Christophe, A. Delanghe, J. Altamura, C. Neels, H. Meltzer, H. Y. Depletion of omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients, 1999.
136. Seko C. Relationship between fatty acid composition in blood and depressive Symptoms in the elderly. Jpn J Hyg. 52:1997;539.
137. Peet M., Murphy B., Shay J., Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry. 43:1998;315-319.
138. Edwards R., Peet M., Shay J., Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord. 48:1998;149-155.
139. Hibbeln J. R., Umhau J. C., George D. T., Salem N. Do plasma polyunsaturates predict hostility and depression. World Rev Nutr Diet. 82:1997;175-186.
140. Hibbeln J. R., Salem N. Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am J Clin Nutr. 62:1995;1-9.
141. Yokogoshi H., Oishi K., Okitsu M. Accumulation of brain tryptophan in rats after administering various fats or fatty acids. Biosci Biotech Biochem. 57:1993;181-184.
142. Kalmijn S., Feskens E. J. M., Launer L. J., Kromhout D. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemol. 145:1997;33-41.
143. Mamalakis G., Kafatos A., Tornaritis M., Alevizos B. Anxiety and adipose essential fatty acid precursors for prostaglandin E1 and E2. J Am Coll Nutr. 17:1998;239-243.
144. Lieb J., Karmali R., Horrobin D. F. Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostaglandins Leukotrienes and Medicine. 10:1983;361-367.
145. Calabrese J. R., Skwerer R. G., Barna B. Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res. 17:1986;41-47.
146. Piccirillo G., Fimognari F. L., Infantino V. High plasma concentrations of cortisol and thromboxane B2 in patients with depression. Am J Med Sci. 307:1994;228-232.
147. Nishino S., Ueno R., Ohishi K., Sakai T., Hayaishi O. Salivary prostaglandin concentrations: possible state indicators for major depression. Am J Psychiatry. 146:1989;365-368.
148. Ohishi K., Ueno R., Nishino S., Sakai T., Hayaishi O. Increased level of salivary prostaglandins in patients with major depression. Biol Psychiatry. 23:1988;326-334.
149. Lowinger P. Prostaglandins and organic affective syndrome. Am J Psychiatry. 146:1989;1646-1647.
150. Mest H. J., Zehl W., Sziegoleit W., Taube Ch., Forster W. Influence of mental stress on plasma level of prostaglandins, thromboxane B2 and circulating platelet aggregates in man. Protaglandin Leukotriene and Medicine. 8:1982;553-563.
151. Ansell D., Belch J. J., Forbes C. D. Depression and prostacyclin infusion. Lancet. 2:1986;509.
152. Gerner R. H., Merrill J. E. Cerebrospinal fluid prostaglandin E in depression, mania, and schizophrenia compared to normals. Biol Psychiatry. 18:1983;565-569.
153. Anton R. F., Ballenger J. C., Lydiard R. B., Laraia M. T., Howell E. F., Gold P. W. CSF prostaglandin-E in agoraphobia with panic attacks. Biol Psychiatry. 26:1989;257-264.
154. Gross H. A., Dunner D. L., Lafleur D., Meltzer H. L., Fieve R. R. Prostaglandin F in patients with primary affective disorder. Biol Psychiatry. 12:1977;347-357.
155. Linnoila M., Whorton A. R., Rubinow D. R., Cowdry R. W., Ninan P. T., Waters R. N. CSF prostaglandin levels in depressed and schizophrenic patients. Arch Gen Psychiatry. 40:1983;405-406.
156. Lloyd D. B. Depression on withdrawal of indomethacin. Brit J Rheum. 31:1992;211.
157. Lee R. E. The influence of psychotropic drugs on prostaglandin biosynthesis. Prostaglandins. 5:1974;63-68.
158. Bekemeier H., Giessler A. J., Vogel E. Influence of MAO-inhibitors, neuroleptics, morphine, mescaline, divascan, aconitine, and pyrogenes on prostaglandin-biosynthesis. Pharmacol Res Commun. 9:1977;587-598.
159. Lambert B., Jacquemin C. Synergic effect of insulin and prostaglandin E1 on stimulated lipolysis. Prostaglandins Med. 5:1980;375-382.
160. Fjalland B. Influence of various substances on prostaglandin biosynthesis by guinea-pig chopped lung. J Pharm Pharmacol. 28:1976;683-686.
161. Mtabaji J. P., Manku M. S., Horrobin D. F. Actions of the tricyclic antidepressant clomipramine on responses to pressor agents. Interactions with prostaglandin E2. Prostaglandins. 14:1977;125-132.
162. Horrobin D. F., Manku M. S., Cunnane S. Regulation of cytoplasmic calcium: interactions between prostaglandins, prostacyclin, thromboxane A2, zinc, copper and taurine. Can J Neurol Sci. 5:1978;93-96.
163. Leaf A., Kang J. X. Omega 3 fatty acids and cardiovascular disease. World Rev Nutr Diet. 83:1998;24-37.
164. Horrobin D. F. Abnormal membrane concentrations of 20 and 22 carbon essential fatty acids: a common link between risk factors and coronary and peripheral vascular disease. Prostaglandins Leukot Essent Fatty Acids. 53:1995;385-396.
165. Renier G., Skamene E., DeSanctis J., Radzioch D. Dietary n-3 polyunsaturated fatty acids prevent the development of atherosclerotic lesions in mice. Modulation of macrophage secretory activities. Arterioscler Thromb. 13:1993;1515-1524.
166. Burr M. L., Fehily A. M., Gilbert J. F. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial DART. Lancet. 2:1989;757-761.
167. de Lorgeril M., Renaud S., Mamelle N. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 343:1994;1454-1459.
168. Christensen J. H., Gustenhoff P., Korup E. Effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomised controlled trial. Br Med J. 312:1996;677-678.
169. Carney R. M., Rich M. W., teVelde A., Saini J., Clark K., Freedland K. E. The relationship between heart rate, heart rate variability and depression in patients with coronary artery disease. J Psychosom Res. 32:1988;159-164.
170. Krittayaphong R., Cascio W. E., Light K. C. Heart rate variability in patients with coronary artery disease: differences in patients with higher and lower depression scores. Psychosom Med. 59:1997;231-235.
171. Horrobin D. F. Fatty acid metabolism in health and disease: the role of delta-6-desaturase. Am J Clin Nutr. 57:1993;732S-737S.
172. Horrobin D. F. Gamma-linolenic acid in the treatment of diabetic neuropathy. Boulton A. J. M. Diabetic Neuropathy. 1997;183-195 Marius Press, Carnforth.
173. Horrobin D. F. Essential fatty acids in the management of impaired nerve function in diabetes. Diabetes. 46 Suppl 2:1997b;S90-S93.
174. Horrobin D. F. Essential fatty acid metabolism in patients with diabetic neuropathy. Prostaglandins Leukot Essent Fatty Acids. 57:1997;256.
175. Gerbi A., Maixent J. M., Ansaldi J. L. Fish oil supplementation prevents diabetes-induced nerve conduction velocity and neuroanatomical changes in rats. J Nutr. 129:1999;207-213.
176. Mori Y., Murakawa Y., Katoh S. Influence of highly purified eicosapentaenoic acid ethyl ester on insulin resistance in the Otsuka Long-Evans Tokushima fatty rat, a model of spontaneous non-insulin-dependent diabetes mellitus. Metabolism. 46:1997;1458-1464.
177. Okuda Y., Mizutani M., Ogawa M. Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus. J Diabetes Complications. 10:1996;280-287.
178. Shimizu H., Ohtani K. -I., Tanaka Y. Increased plasma thrombin-antithrombin III complex levels in non-insulin dependent diabetic patients with albuminuria are reduced by ethyl icosapentatenate. Thromb Haemost. 74:1995;1231-1234.
179. Armesilla A. L., Calvo D., Vega M. A. Structural and functional characterization of the human CD36 gene promoter: identification of a proximal PEBP2/CBF site. J Biol Chem. 271:1996;7781-7787.
180. Abumrad N., Harmon C., Ibrahimi A. Membrane transport of long-chain fatty acids: evidence for a facilitated process. J Lipid Res. 39:1998;2309-2318.
181. Abumrad N. A., el Maghrabi M. R., Amri E. Z., Lopez E., Grimaldi P. A. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J Biol Chem. 268:1993;17665-17668.
182. Aitman T. J., Glazier A. M., Wallace C. A. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet. 21:1999;76-83.
183. Mtabaji J. P., Manku M. S., Horrobin D. F. Release of fatty acids by perfused vascular tissue in normotensive and hypertensive rats. Hypertension. 12:1988;39-45.
184. Mtabaji J. P., Manku M. S., Horrobin D. F. Abnormalities in dihomo-gamma-linolenic acid release in the pathogenesis of hypertension. Am J Hypertens. 6:1993;458-462.
185. Pietsch A., Weber C., Goretzki M., Wabwe P., Lorenz R. n-3 but not n-6 fatty acids reduce the expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Cell Biochem Funct. 13:1995;211-216.
186. Robinson D. R., Knoell C. T., Urakaze M. Suppression of autoimmune disease by omega-3 fatty acids. Biochem Soc Trans. 23:1995;287-291.
187. Volker D., Garg M. Dietary N-3 fatty-acid supplementation in rheumatoid arthritis - mechanisms, clinical outcomes, controversies, and future directions. J Clin Biochem Nutr. 20:1996;83-97.
188. Maes M., Smith R. S. Fatty acids, cytokines, and major depression. Biol Psychiatry. 43:1998;313-314.
189. Purasiri P., McKechnie A., Heys S. D., Eremin O. Modulation in vitro of human natural cytotoxicity, lymphocyte proliferative response to mitogens and cytokine production by essential fatty acids. Immunology. 92:1997;166-172.
190. Hughes D. A., Pinder A. C., Piper Z., Johnson I. T., Lund E. K. Fish oil supplementation inhibits the expression of major histocompatibility complex class II molecules and adhesion molecules on human monocytes. Am J Clin Nutr. 63:1996;267-272.
191. Renz H., Gong J. H., Schmidt A., Nain M., Gemsa D. Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. J Immunol. 141:1988;2388-2393.
192. Davidson J., Bonner S. A., Rotondo D. Eicosapentaenoic acid attenuates the production of pro-inflammatory cytokines in human blood. Br J Pharmacol. 122 Suppl/2:1997;355P.
193. Davidson J., Higgs W., Rotondo D. Eicosapentaenoic acid suppresses the acute phase fever response and increases in blood PGE2 levels. Br J Pharmacol. 122 Suppl/2:1997;356P.
194. Palombo J. D., DeMichele S. J., Lydon E. E. Rapid modulation of lung and liver macrophage phospholipid fatty acids in endotoxemic rats by continuos enteral feeding with n-3 and gamma-linolenic fatty acids. Am J Clin Nutr. 63:1996;208-219.
195. Sanderson P., MacPherson G. G., Jenkins C. H., Calder P. C. Dietary fish oil diminishes the antigen-presentation activity of rat dendritic cells. Biochem Soc Trans. 25:1997;351S.
196. Sanderson P., Yaqoob P., Calder P. C. Effects of dietary lipid manipulation upon rat spleen lymphocyte functions and the expression of lymphocyte surface molecules. J Nutr Environ Med. 5:1995;119-132.
197. Williams J. A., Shacter E. Regulation of macrophage cytokine production by prostaglandin E-2 - Distinct roles of cyclooxygenase-1 and -2. J Biol Chem. 272:1997;25693-25699.
198. Hellerstein M. K., Meydani S. N., Meydani M., Wu K., Dinarello C. A. Interleukin-1-induced anorexia in the rat. Influence of prostaglandins. J Clin Invest. 84:1989;228-235.
199. Meydani S. N., Endres S., Woods M. M. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J Nutr. 121:1991;547-555.
200. Meydani S. N. Effect of (n-3) polyunsaturated fatty acids on cytokine production and their biologic function. Ann Thorac Surg. 12:1996;S8-S14.
201. Endres S., Ghorbani R., Kelley V. E. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 320:1989;265-271.
202. Endres S. N-3 polyunsaturated fatty acids and human cytokine synthesis. Lipids. 31:1996;239-242.
203. Soyland E., Lea T., Sandstad B., Drevon A. Dietary supplementation with very long-chain n-3 fatty acids in man decreases expression of the interleukin-2 receptor (CD25) on mitogen-stimulated lymphocytes from patients with inflammatory skin diseases. Eur J Clin Invest. 24:1994;236-242.
204. Cooper A. L., Gibbons L., Horan M. A., Little R. A., Rothwell N. J. Effect of dietary fish oil supplementation on fever and cytokine production in human volunteers. Clin Nutr. 12:1993;321-328.
205. Grimble R. F., Kappia P. S. Modulation of proinflammatory cytokine biology by unsaturated fatty acids. Z Ernahrungswiss. 37:1998;57-65.
206. Alexander J. W. Immunonutrition: The role of omega-3 fatty acids. Nutrition. 14:1998;627-633.
207. Caughey G. E., Mantzioris E., Gibson R. A., Cleland L. G., James M. The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr. 63:1996;116-122.
208. Calder P. C. N-3 polyunsaturated fatty acids and cytokine production in health and disease. Ann Nutr Metab. 41:1997;203-234.
209. Blok W. L., Katan M. B., van der Meer J W. M. Modulation of inflammation and cytokine production by dietary (n-3) fatty acids. J Nutr. 126:1996;1515-1533.
210. Abbate R., Gori A. M., Martini F. n-3 PUFA supplementation, monocyte PCA expression and interleukin-6 production. Prostaglandins Leukot Essent Fatty Acids. 54:1996;439-444.
211. Jolly C. A., Jiang Y. H., Chapkin R. S., McMurray D. N. Dietary (n-3) polyunsaturated fatty acid suppresses murine lymphoproliferation, interleukin-2 secretion, and the formation of diacylglycerol and ceramide. J Nutr. 127:1997;37-43.
212. May C., Southworth A., Calder P. Inhibition of lymphocyte protein kinase C by unsaturated fatty acids. Biochem Biophys Res Commun. 195:1993;823-828.
213. Sanderson P., Calder P. C. Dietary fish oil appears to prevent the activation of phospholipase C-gamma in lymphocytes. Biochim Biophys Acta. 1392:1998;300-308.
214. Dore Duffy P., Ho S. Y., Donovan C. Cerebrospinal fluid eicosanoid levels: endogenous PG2 and LTC4 synthesis by antigen-presenting cells that migrate to the central nervous system. Neurology. 41:1991;322-324.
215. Sharief M. K., Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med. 325:1991;467-472.
216. Nightingale S., Woo E., Smith A. Red blood cell and adipose tissue fatty acids in mild inactive multiple sclerosis. Acta Neurol Scand. 82:1990;43-50.
217. Holman R., Johnson S., Kokmen E. Deficiencies of polyunsaturated fatty acids and replacement by nonessential fatty acids in plasma lipids in multiple sclerosis. Proc Natl Acad Sci USA. 86:1989;4720-4724.
218. Cunnane S. C., Ho S. Y., Dore Duffy P., Ells K. R., Horrobin D. F. Essential fatty acid and lipid profiles in plasma and erythrocytes in patients with multiple sclerosis. Am J Clin Nutr. 50:1989;801-806.
219. Cendrowski W. Multiple sclerosis and MaxEPA. Br J Clin Practice. 40:1986;365-367.
220. Gallai V., Sarchielli P., Trequattrini A. Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. J Neuroimmunol. 56:1995;143-153.
221. Comings D. E. Pc 1 Duarte, a common polymorphism of a human brain protein, and its relationship to depressive disease and multiple sclerosis. Nature. 277:1979;28-32.
222. Horrobin D. F. Loss of delta-6-desaturase activity as a key factor in aging. Med Hypotheses. 7:1981;1211-1220.
223. Takahashi R., Ito H., Horrobin D. E. Fatty acid composition of serum phospholipids in an elderly institutionalized Japanese population. J Nutr Sci Vitaminol Tokyo. 37:1991;401-409.
224. Bolton-Smith C., Woodward M., Tavendale R. Evidence for age-related differences in the fatty acid composition of human adipose tissue, independent of diet. Eur J Clin Nutr. 51:1997;619-624.
225. Bordoni A., Biagi P. L., Turchetto F., Hrelia S. Aging influence on delta-6-desaturase activity and fatty acid composition of rat liver microsomes. Biochem Int. 17:1988;1001-1009.
226. Cho H. P., Nakamura M. T., Clarke S. D. Cloning, expression, and nutritional regulation of the mammalian delta-6 desaturase. J Biol Chem. 274:1999;471-477.
227. McGahon B., Clements M. P., Lynch M. A. The ability of aged rats to sustain long-term potentiation is restored when the age-related decrease in membrane arachidonic acid concentration is reversed. Neuroscience. 81:1997;9-16.
228. Lynch, M. Analysis of age-related changes in the cerebral cortex of rats: effect of dietary manipulation with arachidonic acid and its precursor gamma-linolenic acid, 1998.
229. Michelson D., Stratakis C., Hill L. Bone mineral density in women with depression. N Engl J Med. 335:1996;1176-1181.
230. Schweiger U., Deuschle M., Korner A. Low lumbar bone mineral density in patients with major depression. Am J Psychiatry. 151:1994;1691-1693.
231. Kruger M. C., Horrobin D. F. Calcium metabolism, osteoporosis and essential fatty acids: a review. Prog Lipid Res. 36:1997;131-151.
232. Hibbeln J. R., Palmer J. W., Davis J. M. Are disturbances in lipid-protein interactions by phospholipase-A2 a predisposing factor in affective illness. Biol Psychiatry. 25:1989;945-961.
233. Risch N. Linkage strategies for genetically complex traits. I. Multilocus models. Am J Hum Genet. 46:1990;222-228.
234. Winkler J. D., Fonteh A. N., Sung C. M. Inhibition of CoA-independent transacylase reduces inflammatory lipid mediators. Adv Prostaglandin Thromhoxane Leukot Res. 23:1995;89-91.
235. Yamashita A., Sugiura T., Waku K. Acyltransferases and transacylases involved in fatty acid remodeling of phospholipids and metabolism of bioactive lipids in mammalian cells. J Biochem. 122:1997;1-16.
236. Balsinde J., Bianco I. D., Ackermann E. J., Conde Frieboes K., Dennis E. A. Inhibition of calcium-independent phospholipase A2 prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages. Proc Natl Acad Sci USA. 92:1995;8527-8531.
237. Svetlov S. I., Liu H., Chao W., Olson M. S. Regulation of platelet-activating factor (PAF) biosynthesis via coenzyme A-independent transacylase in the macrophage cell line IC-21 stimulated with lipopolysaccharide. Biochim Biophys Acta. 1346:1997;120-130.
238. Yamada M., Ichinowatari G., Tanimoto A., Yaginuma H., Ohuchi K. Inhibition of tumor necrosis factor-alpha production by SK&F 98625, a CoA-independent transacylase inhibitor, in cultured rat peritoneal macrophages. Life Sci. 62:1998;297-302.
239. Winkler J. D., Sung C. M., Huang L., Chilton F. H. CoA-independent transacylase activity is increased in human neutrophils after treatment with tumor necrosis factor alpha. Biochim Biophys Acta. 1215:1994;133-140.
240. Winkler J. D., Sung C. M., ChabotFlecher M. beta-Lactams SB 212047 and SB 216754 are irreversible, time-dependent inhibitors of coenzyme A-independent transacylase. Mol Pharmacol. 53:1998;322-329.
241. Chilton F. H., Fonteh A. N., Sung C. M. Inhibitors of CoA-independent transacylase block the movement of arachidonate into 1-ether-linked phospholipids of human neutrophils. Biochemistry. 34:1995;5403-5410.
242. Marshall P. J., Griswold D E., Breton J. Pharmacology of the pyrroloimidazole, SK&F 105809 - I. Inhibition of inflammatory cytokine production and of 5-lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid. Biochem Pharmacol. 42:1991;813-824.
243. Winkler J. D., Fonteh A. N., Sung C. M. Effects of CoA-independent transacylase inhibitors on the production of lipid inflammatory mediators. J Pharmacol Exp Ther. 274:1995;1338-1347.
244. Horrobin D. F., Bennett C. N. New gene targets related to schizophrenia and other psychiatric disorders: enzymes, binding proteins and transport proteins involved in phospholipid and fatty acid metabolism. Prostaglandins Leukot Essent Fatty Acids. 60:1999;111-167.
245. Ewald H., Degn B., Mors O., Kruse T. A. Support for the possible locus on chromosome 4p16 for bipolar affective disorder. Mol Psychiatry. 3:1998;442-448.
246. Finnen M. J., Lovell C. R. Purification and characterisation of phospholipase A2 from human epidermis. Biochem Soc Trans. 19:1991;91S.
247. Horrobin D. F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res. 30:1998;193-208.
248. Stoll A., Severus E., Freeman M. P. Omega-3 fatty acids in bipolar disorder: a double-blind placebo-controlled trial. Arch Gen Psychiatry. 1999.
249. Peet M., Mellor J. Double-blind placebo controlled trial of n-3 polyunsaturatcd fatty acids as an adjunct to neuroleptics. Schizophr Res. 29:1998;160.
250. Kendell R. E. Diagnosis and classification of functional psychoses. Br Med Bull. 43:1987;499-513.
251. Ross B. M., Hudson C., Erlich J., Warsh J. J., Kish S. J. Increased phospholipid breakdown in schizophrenia - Evidence for the involvement of a calcium-independent phospholipase A(2). Arch Gen Psychiatry. 54:1997;487-494.
252. Piomelli D. Eicosanoids in synaptic transmission. Critical Rev Neurobiol. 8:1993;65-83.